High-risk human papillomavirus E6 protein promotes reprogramming of Fanconi anemia patient cells through repression of p53 but does not allow for sustained growth of induced pluripotent stem cells

Journal of Virology

Volumn 88, Issue 19, 2014, Pages 11315-11326

  Chlon, Timothy M ^a   Hoskins, Elizabeth E ^a   Mayhew, Christopher N ^a   Wikenheiser Brokamp, Kathryn A ^a   Davies, Stella M ^a   Mehta, Parinda ^a   Myers, Kasiani C ^a   Wells, James M ^a   Wells, Susanne I ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CELL PROTEIN; PROTEIN E6; PROTEIN E7; PROTEIN P53; PROTEIN TRA 1 60; TRANSCRIPTION FACTOR NANOG; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; HOMEODOMAIN PROTEIN; MEMBRANE ANTIGEN; NANOG PROTEIN, HUMAN; ONCOPROTEIN; PROTEOGLYCAN; REPRESSOR PROTEIN; SMALL INTERFERING RNA; TRA 1 60 ANTIGEN, HUMAN; TRA-1-60 ANTIGEN, HUMAN;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; FANCONI ANEMIA; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; NUCLEAR REPROGRAMMING; ONCOGENE; PLURIPOTENT STEM CELL; PROTEIN ANALYSIS; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; STAINING; VIRUS CELL INTERACTION; CELL DIFFERENTIATION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETIC TRANSDUCTION; GENETICS; KERATINOCYTE; METABOLISM; PATHOLOGY; PRIMARY CELL CULTURE; VIROLOGY;

ALKALINE PHOSPHATASE; ANTIGENS, SURFACE; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; FANCONI ANEMIA; GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; KERATINOCYTES; NUCLEAR REPROGRAMMING; ONCOGENE PROTEINS, VIRAL; PRIMARY CELL CULTURE; PROTEOGLYCANS; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84906971678     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01533-14     Document Type: Article

References (61)

1. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. 2012. The biology and life-cycle of human papillomaviruses. Vaccine 30(Suppl 5):F55-F70. http://dx.doi.org/10.1016/j.vaccine.2012.06.083.
2. Bodily J, Laimins LA. 2011. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol. 19:33-39. http: //dx.doi.org/10.1016/j.tim.2010.10.002.
3. Vande Pol SB, Klingelhutz AJ. 2013. Papillomavirus E6 oncoproteins. Virology 445:115-137. http://dx.doi.org/10.1016/j.virol.2013.04.026.
4. Roman A, Munger K. 2013. The papillomavirus E7 proteins. Virology 445:138-168. http://dx.doi.org/10.1016/j.virol.2013.04.013.
5. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872. http://dx.doi.org/10 .1016/j.cell.2007.11.019.
6. Okita K, Yamanaka S. 2011. Induced pluripotent stem cells: opportunities and challenges. Philos. Trans. R. Soc. Lond. B Biol. Sci. 366:2198-2207. http://dx.doi.org/10.1098/rstb.2011.0016.
7. Polo JM, Anderssen E, Walsh RM, Schwarz BA, Nefzger CM, Lim SM, Borkent M, Apostolou E, Alaei S, Cloutier J, Bar-Nur O, Cheloufi S, Stadtfeld M, Figueroa ME, Robinton D, Natesan S, Melnick A, Zhu J, Ramaswamy S, Hochedlinger K. 2012. A molecular roadmap of reprogramming somatic cells into iPS cells. Cell 151:1617-1632. http://dx.doi .org/10.1016/j.cell.2012.11.039.
8. Banito A, Gil J. 2010. Induced pluripotent stem cells and senescence: learning the biology to improve the technology. EMBO Rep. 11:353-359. http://dx.doi.org/10.1038/embor.2010.47.
9. Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, Geti I, Pinho S, Silva JC, Azuara V, Walsh M, Vallier L, Gil JS. 2009. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev. 23:2134-2139. http://dx.doi.org/10.1101/gad.1811609.
10. Marion RM, Strati K, Li H, Murga M, Blanco R, Ortega S, Fernandez-Capetillo O, Serrano M, Blasco MA. 2009. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 460:1149-1153. http://dx.doi.org/10.1038/nature08287.
11. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM, Belmonte JCI. 2009. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 460:1140-1144. http: //dx.doi.org/10.1038/nature08311.
12. Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K-I, Shibata T, Kunisada T, Takahashi M, Takahashi J, Saji H, Yamanaka S. 2011. A more efficient method to generate integration-free human iPS cells. Nat. Methods 8:409-412. http://dx.doi.org/10.1038/nmeth.1591.
13. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S. 2009. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460:1132-1135. http://dx.doi .org/10.1038/nature08235.
14. Ruiz S, Panopoulos AD, Herrerias A, Bissig KD, Lutz M, Berggren WT, Verma IM, Izpisua Belmonte JC. 2011. A high proliferation rate is required for cell reprogramming and maintenance of human embryonic stem cell identity. Curr. Biol. 21:45-52. http://dx.doi.org/10.1016/j.cub .2010.11.049.
15. Cervantes RB, Stringer JR, Shao C, Tischfield JA, Stambrook PJ. 2002. Embryonic stem cells and somatic cells differ in mutation frequency and type. Proc. Natl. Acad. Sci. U. S. A. 99:3586-3590. http://dx.doi.org/10 .1073/pnas.062527199.
16. Liu JC, Guan X, Ryan JA, Rivera AG, Mock C, Agarwal V, Letai A, Lerou PH, Lahav G. 2013. High mitochondrial priming sensitizes hESCs to DNA-damage-induced apoptosis. Cell Stem Cell 13:483-491. http://dx .doi.org/10.1016/j.stem.2013.07.018.
17. Serrano L, Liang L, Chang Y, Deng L, Maulion C, Nguyen S, Tischfield JA. 2011. Homologous recombination conserves DNA sequence integrity throughout the cell cycle in embryonic stem cells. Stem Cells Dev. 20:363-374. http://dx.doi.org/10.1089/scd.2010.0159.
18. Smith AJ, Nelson NG, Oommen S, Hartjes KA, Folmes CD, Terzic A, Nelson TJ. 2012. Apoptotic susceptibility to DNA damage of pluripotent stem cells facilitates pharmacologic purging of teratoma risk. Stem Cells Transl. Med. 1:709-718. http://dx.doi.org/10.5966/sctm.2012-0066.
19. Fung H, Weinstock DM. 2011. Repair at single targeted DNA doublestrand breaks in pluripotent and differentiated human cells. PLoS One 6:e20514. http://dx.doi.org/10.1371/journal.pone.0020514.
20. Momcilovic O, Knobloch L, Fornsaglio J, Varum S, Easley C, Schatten G. 2010.DNAdamage responses in human induced pluripotent stem cells and embryonic stem cells. PLoS One 5:e13410. http://dx.doi.org/10.1371 /journal.pone.0013410.
21. Dumitru R, Gama V, Fagan BM, Bower JJ, Swahari V, Pevny LH, Deshmukh M. 2012. Human embryonic stem cells have constitutively active Bax at the Golgi and are primed to undergo rapid apoptosis. Mol. Cell 46:573-583. http://dx.doi.org/10.1016/j.molcel.2012.04.002.
22. Romick-Rosendale LE, Lui VWY, Grandis JR, Wells SI. 2013. The Fanconi anemia pathway: repairing the link between DNA damage and squamous cell carcinoma. Mutat. Res. 743-744:78-88. http://dx.doi.org /10.1016/j.mrfmmm.2013.01.001.
23. Kee Y, D'Andrea AD. 2010. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev. 24:1680-1694. http://dx .doi.org/10.1101/gad.1955310.
24. Kottemann MC, Smogorzewska A. 2013. Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature 493:356-363. http://dx.doi .org/10.1038/nature11863.
25. Raya A, Rodriguez-Piza I, Guenechea G, Vassena R, Navarro S, Barrero MJ, Consiglio A, Castella M, Rio P, Sleep E, Gonzalez F, Tiscornia G, Garreta E, Aasen T, Veiga A, Verma IM, Surralles J, Bueren J, Izpisua Belmonte JC. 2009. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 460:53-59. http: //dx.doi.org/10.1038/nature08129.
26. Muller LUW, Milsom MD, Harris CE, Vyas R, Brumme KM, Parmar K, Moreau LA, Schambach A, Park I-H, London WB, Strait K, Schlaeger T, DeVine AL, Grassman E, D'Andrea A, Daley GQ, Williams DA. 2012. Overcoming reprogramming resistance of Fanconi anemia cells. Blood 119:5449-5457. http://dx.doi.org/10.1182/blood-2012-02-408674.
27. Gonzalez F, Georgieva D, Vanoli F, Shi Z-D, Stadtfeld M, Ludwig T, Jasin M, Huangfu D. 2013. Homologous recombination DNA repair genes play a critical role in reprogramming to a pluripotent state. Cell Rep. 3:651-660. http://dx.doi.org/10.1016/j.celrep.2013.02.005.
28. Yung SK, Tilgner K, Ledran MH, Habibollah S, Neganova I, Singhapol C, Saretzki GC, Stojkovic M, Armstrong L, Przyborski SA, Lako M. 2013. Human pluripotent stem cell models of Fanconi anemia deficiency reveal an important role for Fanconi anemia proteins in cellular reprogramming and survival of haematopoietic progenitors. Stem Cells 31: 1022-1029. http://dx.doi.org/10.1002/stem.1308.
29. Huibregtse JM, Scheffner M, Howley PM. 1991. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 10:4129-4135.
30. Gewin L, Myers H, Kiyono T, Galloway DA. 2004. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev. 18:2269-2282. http://dx.doi.org /10.1101/gad.1214704.
31. Liu X, Dakic A, Zhang Y, Dai Y, Chen R, Schlegel R. 2009. HPV E6 protein interacts physically and functionally with the cellular telomerase complex. Proc. Natl. Acad. Sci. U. S. A. 106:18780-18785. http://dx.doi .org/10.1073/pnas.0906357106.
32. Veldman T, Liu X, Yuan H, Schlegel R. 2003. Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl. Acad. Sci. U. S. A. 100:8211-8216. http://dx.doi.org/10.1073/pnas.1435900100.
33. Munger K, Scheffner M, Huibregtse JM, Howley PM. 1992. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv. 12:197-217.
34. Jones DL, Alani RM, Munger K. 1997. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev. 11:2101-2111. http://dx.doi.org/10.1101/gad.11.16.2101.
35. Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA. 1997. Inhibition of CDK activity and PCNA-dependentDNAreplication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 11:2090-2100. http://dx.doi.org/10.1101/gad.11.16.2090.
36. Hoskins EE, Morris TA, Higginbotham JM, Spardy N, Cha E, Kelly P, Williams DA, Wikenheiser-Brokamp KA, Duensing S, Wells SI. 2009. Fanconi anemia deficiency stimulates HPV-associated hyperplastic growth in organotypic epithelial raft culture. Oncogene 28:674-685. http: //dx.doi.org/10.1038/onc.2008.416.
37. Warlich E, Kuehle J, Cantz T, Brugman MH, Maetzig T, Galla M, Filipczyk AA, Halle S, Klump H, Scholer HR, Baum C, Schroeder T, Schambach A. 2011. Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming. Mol. Ther. 19:782-789. http://dx.doi.org/10.1038/mt.2010.314.
38. Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Tolle K, Hoskins EE, Kalinichenko VV, Wells SI, Zorn AM, Shroyer NF, Wells JM. 2011. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature 470:105-109. http://dx.doi.org/10.1038 /nature09691.
39. Navarro S, Moleiro V, Molina-Estevez FJ, Lozano ML, Chinchon R, Almarza E, Quintana-Bustamante O, Mostoslavsky G, Maetzig T, Galla M, Heinz N, Schiedlmeier B, Torres Y, Modlich U, Samper E, Ri´o P, Segovia JC, Raya A, Gu¨enechea G, Izpisua-Belmonte JC, Bueren JA. 2014. Generation of iPSCs from genetically corrected Brca2 hypomorphic cells: implications in cell reprogramming and stem cell therapy. Stem Cells 32:436-446. http://dx.doi.org/10.1002/stem.1586.
40. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG, Hochedlinger K. 2009. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 460:1145-1148. http://dx.doi.org/10.1038/nature08285.
41. Liu Y, Chen JJ, Gao Q, Dalal S, Hong Y, Mansur CP, Band V, Androphy EJ. 1999. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J. Virol. 73:7297-7307.
42. Zimmermann H, Degenkolbe R, Bernard H-U, O'Connor MJ. 1999. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J. Virol. 73:6209-6219.
43. Klingelhutz AJ, Foster SA, McDougall JK. 1996. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380:79-82. http://dx.doi.org/10.1038/380079a0.
44. Dalal S, Gao Q, Androphy EJ, Band V. 1996. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. J. Virol. 70: 683-688.
45. Pagano G, Talamanca AA, Castello G, d'Ischia M, Pallardo FV, Petrovic S, Porto B, Tiano L, Zatterale A. 2013. Bone marrow cell transcripts from Fanconi anaemia patients reveal in vivo alterations in mitochondrial, redox and DNA repair pathways. Eur. J. Haematol. 91:141-151. http://dx .doi.org/10.1111/ejh.12131.
46. Kumari U, Ya Jun W, Huat Bay B, Lyakhovich A. 2014. Evidence of mitochondrial dysfunction and impaired ROS detoxifying machinery in Fanconi anemia cells. Oncogene 33:165-172. http://dx.doi.org/10.1038 /onc.2012.583.
47. Lyakhovich A. 2013. Damaged mitochondria and overproduction of ROS in Fanconi anemia cells. Rare Dis. 1:e24048. http://dx.doi.org/10.4161 /rdis.24048.
48. Ravera S, Vaccaro D, Cuccarolo P, Columbaro M, Capanni C, Bartolucci M, Panfoli I, Morelli A, Dufour C, Cappelli E, Degan P. 2013. Mitochondrial respiratory chain complex I defects in Fanconi anemia complementation group A. Biochimie 95:1828-1837. http://dx.doi.org /10.1016/j.biochi.2013.06.006.
49. Mathieu J, Zhou W, Xing Y, Sperber H, Ferreccio A, Agoston Z, Kuppusamy KT, Moon RT, Ruohola-Baker H. 2014. Hypoxia-inducible factors have distinct and stage-specific roles during reprogramming of human cells to pluripotency. Cell Stem Cell 14:592-605. http://dx.doi.org /10.1016/j.stem.2014.02.012.
50. Capanni C, Bruschi M, Columbaro M, Cuccarolo P, Ravera S, Dufour C, Candiano G, Petretto A, Degan P, Cappelli E. 2013. Changes in vimentin, lamin A/C and mitofilin induce aberrant cell organization in fibroblasts from Fanconi anemia complementation group A (FA-A) patients. Biochimie 95:1838-1847. http://dx.doi.org/10.1016/j.biochi.2013 .06.024.
51. Park E, Kim H, Kim JM, Primack B, Vidal-Cardenas S, Xu Y, Price BD, Mills AA, D'Andrea AD. 2013. FANCD2 activates transcription of TAp63 and suppresses tumorigenesis. Mol. Cell 50:908-918. http://dx.doi.org/10 .1016/j.molcel.2013.05.017.
52. Tilgner K, Neganova I, Moreno-Gimeno I, Al-Aama JY, Burks D, Yung S, Singhapol C, Saretzki G, Evans J, Gorbunova V, Gennery A, Przyborski S, Stojkovic M, Armstrong L, Jeggo P, Lako M. 2013. A human iPSC model of ligase IV deficiency reveals an important role for NHEJmediated-DSB repair in the survival and genomic stability of induced pluripotent stem cells and emerging haematopoietic progenitors. Cell Death Differ. 20:1089-1100. http://dx.doi.org/10.1038/cdd.2013.44.
53. Hoskins EE, Morreale RJ, Werner SP, Higginbotham JM, Laimins LA, Lambert PF, Brown DR, Gillison ML, Nuovo GJ, Witte DP, Kim MO, Davies SM, Mehta PA, Butsch Kovacic M, Wikenheiser-Brokamp KA, Wells SI. 2012. The Fanconi anemia pathway limits human papillomavirus replication. J. Virol. 86:8131-8138. http://dx.doi.org/10.1128/JVI .00408-12.
54. Park JW, Pitot HC, Strati K, Spardy N, Duensing S, Grompe M, Lambert PF. 2010. Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer. Cancer Res. 70:9959-9968. http://dx.doi.org/10.1158/0008-5472 .CAN-10-1291.
55. Park JW, Shin MK, Lambert PF. 2014. High incidence of female reproductive tract cancers in FA-deficient HPV16-transgenic mice correlates with E7's induction ofDNAdamage response, an activity mediated by E7's inactivation of pocket proteins. Oncogene 33:3383-3391. http://dx.doi .org/10.1038/onc.2013.327.
56. Park JW, Shin MK, Pitot HC, Lambert PF. 2013. High incidence of HPV-associated head and neck cancers in FA deficient mice is associated with E7's induction of DNA damage through its inactivation of pocket proteins. PLoS One 8:e75056. http://dx.doi.org/10.1371/journal.pone .0075056.
57. van Zeeburg HJT, Snijders PJF, Wu T, Gluckman E, Soulier J, Surralles J, Castella M, van der Wal JE, Wennerberg J, Califano J, Velleuer E, Dietrich R, Ebell W, Bloemena E, Joenje H, Leemans CR, Brakenhoff RH. 2008. Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J. Natl. Cancer Inst. 100:1649-1653. http://dx.doi.org/10.1093/jnci/djn366.
58. Alter BP, Giri N, Savage SA, Quint WGV, de Koning MNC, Schiffman M. 2013. Squamous cell carcinomas in patients with Fanconi anemia and dyskeratosis congenita: a search for human papillomavirus. Int. J. Cancer 133:1513-1515. http://dx.doi.org/10.1002/ijc.28157.
59. de Araujo MR, Rubira-Bullen IRF, Santos CF, Dioni´sio TJ, Bonfim CMS, De Marco L, Gillio-Tos A, Merletti F. 2011. High prevalence of oral human papillomavirus infection in Fanconi's anemia patients. Oral Dis. 17:572-576. http://dx.doi.org/10.1111/j.1601-0825.2011.01803.x.
60. Kutler DI, Auerbach AD, Satagopan J, Giampietro PF, Batish PF, Batish SD, Huvos AG, Goberdhan A, Shah JP, Singh B. 2003. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch. Otolaryngol. Head Neck Surg. 129:106-112. http://dx.doi .org/10.1001/archotol.129.1.106.
61. Voorhoeve PM, Agami R. 2003. The tumor-suppressive functions of the human INK4A locus. Cancer Cell 4:311-319. http://dx.doi.org/10.1016 /S1535-6108(03)00223-X.